Adesh University Journal of Medical Sciences & Research
Cure8 research brief
Why This Matters
People with UC who need biologic therapy during conception or pregnancy often face limited evidence about safety and effectiveness; this case suggests ustekinumab may be an option when other drugs fail or are stopped for pregnancy planning.
Who Should Pay Attention
Pregnant-patients, clinicians, patients-on-biologics
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article is a case report of a 30‑year‑old woman with moderate‑to‑severe ulcerative colitis who, after stopping tofacitinib to try to conceive, had treatment complications and disease flares; ustekinumab was started as rescue therapy, led to clinical and biochemical remission, and the patient subsequently had an uneventful pregnancy and delivered a healthy infant.
The report highlights ustekinumab used successfully in pregnancy for refractory UC when prior therapies (tofacitinib, azathioprine, adalimumab) were ineffective or not tolerated.
It’s a single‑patient case report and does not establish safety or efficacy for all patients; clinical decisions should be individualized with a treating gastroenterologist and obstetrician. The article’s structured content is an abstract/case report from a medical journal; Cure8 did not review additional data beyond the provided text.
Keep In Mind
Single‑patient case report; not a substitute for clinical guidelines or specialist advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAdesh University Journal of Medical Sciences & Research
PublisherScientific Scholar
AuthorsJonnalagadda Vihari, Anuraag Jena, Girish Kumar Pati +1 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
IBD and Pregnancy Risks: Few Women Discuss Contraception With Their IBD Specialist
Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
DailyMed label update for AMJEVITA
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...